Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1996-04-02
1999-10-05
Stucker, Jeffrey
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
435 5, 4241601, 530412, 530806, A61K 3921, A61K 3942, C12Q 170, A23J 100
Patent
active
059619848
ABSTRACT:
Isolated and purified envelope protein of HTLV-I is provided devoid of non-envelope protein of HTLV-I and having substantially the same conformation as the envelope protein in native HTLV-I. The protein is produced recombinantly using a dual vaccinia/T7 polymerase system. Non-glycosylated and glycosylated forms of the protein are produced. Glycosylated forms are recognized by antibodies specific for the envelope protein of HTLV-I. Monoclonal antibodies are provided which are specific for the HTLV-I envelope protein and non-binding to HTLV-I envelope protein in denatured form. The HTLV-I envelope protein is cross-reactive with antibodies of HTLV-II and STLV. The envelope protein is useful in diagnosis of infection by HTLV-I and HTLV-II.
REFERENCES:
Arp et al., Expression and immunogenicity of the entire human T cell leukaemia virus type I envelope protein produced in a baculovirus system, J. Gen. Virol., 74, 211-222, 1993.
Robert-Guroff, M., Nakao, Y., Notake, K. Ito, Y., Sliski, A., and R.C. Gallo. 1982. Natural antibodies to human retrovirus HTLV in a cluster of Japanese patients with adult T cell leukemia. Science. 215:975-978.
Yoshida, M., Seiki, M., Yamaguchi, K., and K. Takatsuki. 1984. Monoclonal integration of human T-cell leukemia provirus in all primary tumours of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc. Natl. Acad. Sci. USA. 81:2534-2537.
Osame, M., Usuku, K., Izumo, S., Ijichi, N., Amitani, H., Igata, A., Matsumoto, M., and M. Tara. 1986. HTLV-I Associated Myelopathy, a new clinical entity. Lancet. 1:1031-1032.
Lagrenade, L., Hanchard, B., Fletcher, V., Cranston, B., and W. Blattner. 1990. Infective dermatitis of Jamaican children: a marker for HTLV-I infection. Lancet. 336:1345-1347.
De, B., Lairmore, M., Griffis, K., Williams, L., Villinger, F., Quinn, T., Brown, C., Nzilambi, Sugimoto, M., Araki, S., and T. Folks. 1991. Comparative analysis of nucleotide sequences of the partial envelope gene (5' domain) among human T-lymphotropic virus type (HTLV-I) isolates. Virology. 182:413-419.
Komurian, F., Pelloguin, F., and G. De The. 1991. In vivo genetic variability of human T-cell leukemia virus type I depends more upon geography than upon pathologies. J. Virol. 65:3770-3778.
Pique, C., Tursz, T., and M.-C. Dokhelar. 1990. Mutations introduced along the HTLV-I envelope gene result in a non-functional protein: a basis for envelope conservation EMBO J. 9:4243-4248.
Pique, C., Pham, D., Tursz, T., and M.-C. Dokhelar. 1992. Human T-cell Leukemia Virus Type I envelope protein maturation process: Requirements for syncytium formation. J. Virol. 66:906-913.
Arp, J., Ford, C., Palker, T., King, E., and G. Dekaban. 1993. Expression and immunogenicity of the entire human T-cell leukaemia virus type I envelope protein produced in a baculovirus system. J. Gen. Virol. 74:211-222.
Manca, F., Li Pira, G., Fenoglio, D., Valle, M.T., Kunkl, A., Ferraris, A., Mortara, L., Balderas, R., Arp, J., Baccala, R., Dekaban, G., Dalgleish, A.G., and A.N. Theofilopoulos. 1995. Recognition of HTLV-I envelope protein by human CD4+ T cell lines generated from HTLV-I seronegative individuals. Blood. 85:1547-1554.
Ford, C., Arp, J., King, E., Dekaban, G.A. and T. Palker. 1991. Expression and imunogenicity of HTLV-I envelope proteins by recombinant vaccinia virus, pp. 253-258. In R.M. Chanock, et al. (eds.), Vaccines 91: Modern Approaches to New Vaccines Cold Spring Harbour Laboratory, New York.
Ford, C.M., Arp, J., Palker, T.J. King, E.E., and G.A. Dekaban. 1992. Characterizatino of the antibody response to three different versions of the HTLV-I envelope protein expressed by recombinant vaccinia viruses: Induction of neutralizing antibody. Virology. 191:448-453.
Ratner, L., Josephs, S., Starcich B., Hahn, B., Shaw, G., Gallo, R. and F. Wong-Staal. 1985. Nucleotide sequence analysis of a variant Human T-cell Leukemia Virus (HTLV-lb) provirus with a deletion in pX-I. J. Virol. 54:781-790.
Elroy-Stein, O., Fuerst, T., and B. Moss. 1989. Cap-independent translation of mRNA conferred by encephalomyocarditis virus 5' sequence improves the performance of the vaccinia virus/bacteriophage T7 hybrid expression system. Proc. Natl. Acad. Sci. USA. 86:6126-6130.
Mackett, M., Smith, G., and B. Moss. 1984. General method for the production and selection of infectious vaccinia virus recombinants expressing foreign genes. J. Virol. 49:857-864.
Fuerst, T., Niles, E., Studier, F., and B. Moss. 1986. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc. Natl. Acad. Sci. USA. 83:8122-8126.
Foung, S. and S. Perkins. 1989. Electric field-induced cell fusion and human monoclonal antibodies. J. Immunol. Methods. 116:117-122.
Perkins, S. and S. Foung. 1995. Stabilizing antibody secretino of human Epstein-Barr virus activated B. lymphocytes with hybridoma formatino by electrofusion. In Nickoloff, J. (ed.), Protocols for electroporation and electrofusion of plant and animal cells, in press. Humana Press, New Jersey.
Palker, T., Tanner, M., Scearce, R., Streilein, R., Clark, M. and B. Haynes. 1989. Mapping of immunogenic regions of human T-cell leukemia type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46. J. Immunol. 142:971-978.
Giri, A., Markham, P., Digilio, L., Hurteau, G., Gallo, R., and G. Franchini, 1994. Isolation of a novel simian T-cell lymphotropic virus from Pan paniscus that is distantly related to the human T-cell leukemia/lymphotropic virus types I and II. J. Virol. 68:8392-8395.
Matsushita, S., Robert-Guroff, M., Trepel, J., cossman, J., Mitsuya, H., and S. Broder. 1986. Human monoclonal antibody directed against an envelope glycoprotein of human T-cell leukemia virus type I. Proc. Natl. Acad. Sci. USA. 83:2672-2676.
Plummer, T., Jr., Elder, J., Alexander S., Phelan, A., and A. Tarentino. 1984. Demonstration of peptide: N-glycosidase F activity in endo-beta-N-acetylglucoaminidase F preparations. J. Biol. Chem. 259:10700-10704.
Geyer, H., Holschbach, D., Hunsmann, G., and J. Schneider. 1988. Carbohydrates of human immunodeficiency virus: structures of oligosaccharides linked to the envelope glycoproteins 120. J. Biol. Chem. 263:11760-11767.
Komfeld, R., and S. Komfeld. 1985. Assembly of asparagine-linked oligosaccharides. Ann. Rev. Biochem. 54:631-664.
Seiki, M., Hattori, S., Hirayama, Y., and M. Yoshida. 1983. Human adult T-cell leukemia virus: Complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. Proc. Natl. Acad. Sci. USA. 80:3618-3622.
Chen, Y., Lee, T., Samuel, K., Okayama, A., Tachibana, N., Miyoshi, I., Papas, T., and M. Essex, 1989. Antibody reactivity to different regions of human T-cell leukemia virus type I gp61 in infected people. Journal of Virology 63:4952-4957.
Kiyokawa, T., Yoshikura, H., Hattori, S., Seiki, M., and Yoshida, M. 1984. Envelope proteins of human T-cell leukemia virus: Expression in Escherischia coli and its application to studies of env gene functions. Proceeding of the National Academy of Science, U.S.A. 81:6202-6206.
Kuga, T., Hattori, S., Yoshida, M., and T. Taniguchi. 1986. Expression of human t-cell leukemia virus type I envelope protein in Saccharmyces cerevisiae. Gene. 44:337-340.
Samuel, K., Lautenberger, J., Jorcyk, C., Josephs, S., Wong-Staal, F., and T. Papas. 1984. Diagnostic potential for human malignancies of bacterially produced HTLV-I envelope glycoprotein. Science. 226:1094-1097.
Vile, R., Schulz, T., Danos, O., Collins, M., and R. Weiss, 1991. A Murine cell line producing HTLV-I pseudotype virions carrying a selectable marker gene. Virology. 180:420-424.
Sattentau, Q. and J. Moore. 1995. HIV-1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182:185-196.
Stamatatos, L. and C. Cheng-Mayer. 1995. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon vir
Arp Jacqueline
Dekaban Gregory A.
Foung Steven Kok Hing
Park Hankyel T.
Stanford University
Stucker Jeffrey
University of Western Ontario
LandOfFree
Human T-cell lymphotropic virus type I envelope protein and huma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human T-cell lymphotropic virus type I envelope protein and huma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human T-cell lymphotropic virus type I envelope protein and huma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1168447